You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company is getting ready to offer cancer patients every type of molecular cancer diagnostics, including testing for minimal residual disease.
Exact's planned acquisition of Ashion, a sequencing lab based in Arizona, builds on the company's licensing of the TARDIS liquid biopsy technology from TGen in January.
The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.
The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
Palmetto has expanded the local coverage determination for the Guardant360 liquid biopsy assay to be used with the majority of advanced solid tumors.
In a proof-of-principle study, Ohio State University researchers compared the nanopore sequencing assay to short-read sequencing and capillary electrophoresis.
The companies will use Foundation Medicine's FoundationOne CDx test as the baseline to define a set of unique variants that the codeveloped assays will monitor.
The team analyzed multigene panel test data from Ambry Genetics for 165,000 individuals, focusing on hereditary cancer risk related to 32 genes in six cancer types.
The Navify software, which Roche launched today, provides annotation, interpretation, and clinical reporting of next-generation sequencing tests for cancer.